The CIBBIM has a largely recognized experience with research and development involving industrial partnerships. Particularly with Biotech and Pharma companies. The obtantion of 6 patents (two of them under process) related to new disease biomarkers and therapeutic targets in the last 4 years are a good example of its successful collaborative program. 

The CIBBIM is eager to push forward its Corporate Program to further strength its ties with industrial Bio-Pharmaceutical R+D. For this, CIBBIM launches 4 alternative Industrial Transfer&Service Programs related to the design and validation of new nanomedicines and nanodiagnostic systems.

All programs will allow to design specific in-house research protocols according to end-user needs. Use of some equipments or experimental models might be subject to previous obtention of specific comercial licences or granted permission for comecial use.  

1. THE “DISCOVERY” PROGRAM: Identification of Specific Disease Biomarkers and Therapeutic Leads. We will use High-Throughput strategies and in silico approaches to find the specific disease biomarkers and target candidates for therapeutic intervention you’re looking for. Additional in vitro (yeast, worm and human cellular models) and in vivo (mice, rat, rabbit, goat and pig) models are also available for detection of molecular partners and pathways of your interest.

2. “PUT IT TO THE TEST” PROGRAM: We will use our in vitro and in vivo models (including panels of human samples: tissue, cells, blood, sera and urine)  to test the efficacy and sensitivity of your biomarkers and to perform functional molecular analysis of your therapeutic candidates. We can also test toxicity, biodistribution and farmacokinetics of your lead compounds as well as their therapeutic activity. Orientatively, in vitro assays should include hemo- and cytotoxicity, cell proliferation and apoptosis, and cell cycle analysis. In vivo assays should provide information about body distribution, stability of compounds, organ-specific toxicology, compound clearance, therapeutic activity and efficacy, and preclinical data (IC50, single dose and multiple dose administration).   

3. THE “RECOVERY” PROGRAM: Got nice leads showing too high levels of toxicity? Could your compound be re-designed to wider its therapeutic window? Nanotechnological approaches based on biodegradable polymers have been successful into decreasing the toxicity levels of chemically re-designed drugs without altering their therapeutic activities. Our Recovery Program is intended to re-design your drug into a new nanomedicine conjugate with better performances, allowing the recovery of some of your leads for your company’s portfolio.

4. THE “DEVELOPMENT” PROGRAM: This program is intended to design entirely new nanomedicine conjugates for specific human disease targeted therapies or new imaging diagnostic tools. Biodegradable polymers with an adequate targeting system will be used as nanocarriers either for drug compounds or nucleic acid and protein treatments (siRNA, dominant negative proteins). The program will take over all steps of development from the initial design of the drugged nanoconjugate to its preclinical validation. These nanoconjugates are considered as new patentable chemical entities even if active known compounds are delivered. The latter could be a very useful alternative for those drugs which have gone into the generic market or are becoming close to loss protection (patent expiration).